The median OS observed in our trial cohort of patients with LMD was 10.5 months and was 11.9 months in patients with advanced EGFR-mutated NSCLC without evidence of LMD enrolled in the HERTHENA-Lung01 trial15. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.